Hiromi Matsuda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiromi Matsuda has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Hirotsugu Okamoto
Department of Anesthesiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Kanagawa 252-0375, Japan
3 shared publications- Akihiro Tamaki
Department of Gastroenterology Kitasato University School of Medicine Sagamihara Kanagawa Japan
1 shared publication Akiko Katsuike
Department of Anesthesiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Kanagawa 252-0375, Japan
1 shared publication- Atsushi Yamashita
Department of Molecular Pharmacology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Japan; Department of Anesthesiology, Kitasato University School of Medicine, Sagamihara, Japan
1 shared publication Chie Kurashige
Department of Anesthesiology (H.M., S.T., C.K., H.O.), School of Medicine, Kitasato University, Sagamihara, Kanagawa, Japan
1 shared publicationChika Kusano
Department of Gastroenterology Kitasato University School of Medicine Kanagawa Japan
1 shared publication
Latest Publications
- Open Access
Evaluating a Modified American Society of Anesthesiologists Physical Status‐Based Sedation Management System for Pancreatobiliary Endoscopy: A Prospective Feasibility Study
Objectives: To prospectively evaluate the feasibility of implementing a modified American Society of Anesthesiologists Physical Status (ASA‐PS)‐based sedation management system for endoscopist‐managed sedation in pancreatobiliary endoscopy. Methods: This single‐center, single‐arm prospective feasibility study involved 2000 patients (2024–2025). Sedation risk was stratified using a modified ASA‐PS classification system combined with predefined high‐risk clinical factors (severe obesity, obstructive sleep apnea requiring continuous positive airway pressure, chronic obstructive pulmonary disease requiring home oxygen therapy, reduced functional capacity, and difficult sedation history). Patients meeting high‐risk criteria underwent pre‐procedural anesthesiologist assessment to determine sedation providers. The primary outcome was sedation‐related adverse event (SRAE) incidence during endoscopist‐managed sedation. The secondary outcomes were the sedation success rate and SRAE‐associated risk factors. Results: Among 2000 patients, 231 (11.6%) were classified as having high risk for sedation. Post‐assessment, anesthesiologists and endoscopists managed sedation for 86 (4.3%) and 1914 (95.7%) patients, respectively. In the endoscopist‐managed group, SRAEs occurred in 63 patients (3.3%), corresponding to a success rate of 96.7%. No patient required tracheal intubation or conversion to general anesthesia. In multivariable analysis, endoscopic ultrasonography‐guided sampling was independently associated with reduced SRAEs (odds ratio 0.407, 95% confidence interval 0.184–0.899; p = 0.026); no independent predictors of increased SRAEs were identified. Conclusions: The modified ASA‐PS‐based sedation management system may be a feasible approach in settings with limited anesthesiology resources, warranting further validation. Trial Registration: UMIN000053211
Open AccessEvaluating a Modified American Society of Anesthesiologists Physical Status‐Based Sedation Management System for Pancreatobiliary Endoscopy: A Prospective Feasibility Study
Objectives: To prospectively evaluate the feasibility of implementing a modified American Society of Anesthesiologists Physical Status (ASA‐PS)‐based sedation management system for endoscopist‐managed sedation in pancreatobiliary endoscopy. Methods: This single‐center, single‐arm prospective feasibility study involved 2000 patients (2024–2025). Sedation risk was stratified using a modified ASA‐PS classification system combined with predefined high‐risk clinical factors (severe obesity, obstructive sleep apnea requiring continuous positive airway pressure, chronic obstructive pulmonary disease requiring home oxygen therapy, reduced functional capacity, and difficult sedation history). Patients meeting high‐risk criteria underwent pre‐procedural anesthesiologist assessment to determine sedation providers. The primary outcome was sedation‐related adverse event (SRAE) incidence during endoscopist‐managed sedation. The secondary outcomes were the sedation success rate and SRAE‐associated risk factors. Results: Among 2000 patients, 231 (11.6%) were classified as having high risk for sedation. Post‐assessment, anesthesiologists and endoscopists managed sedation for 86 (4.3%) and 1914 (95.7%) patients, respectively. In the endoscopist‐managed group, SRAEs occurred in 63 patients (3.3%), corresponding to a success rate of 96.7%. No patient required tracheal intubation or conversion to general anesthesia. In multivariable analysis, endoscopic ultrasonography‐guided sampling was independently associated with reduced SRAEs (odds ratio 0.407, 95% confidence interval 0.184–0.899; p = 0.026); no independent predictors of increased SRAEs were identified. Conclusions: The modified ASA‐PS‐based sedation management system may be a feasible approach in settings with limited anesthesiology resources, warranting further validation. Trial Registration: UMIN000053211
- Open Access
- 20 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 10107
RAMP1 Signaling Mitigates Acute Lung Injury by Distinctively Regulating Alveolar and Monocyte-Derived Macrophages
Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that induces cytokine hypersecretion. Receptor activity-modifying protein (RAMP) 1, a subunit of the calcitonin gene-related peptide (CGRP) receptor, regulates the production of cytokines. This study examined the role of RAMP1 signaling during lipopolysaccharide (LPS)-induced acute lung injury (ALI). LPS administration to wild-type (WT) mice depleted alveolar macrophages (AMs) and recruited monocyte-derived macrophages (MDMs) and neutrophils. RAMP1-deficient (RAMP1−/−) mice exhibited higher lung injury scores, cytokine levels, and cytokine-producing neutrophil infiltration. RAMP1-deficient AMs produced more cytokines in response to LPS than WT AMs. Adoptive transfer of RAMP1-deficient AMs to RAMP1−/− mice increased cytokine levels and neutrophil accumulation compared to the transfer of WT AMs. RAMP1−/− mice had reduced MDM recruitment and lower pro-inflammatory and reparative macrophage profiles. Cultured bone marrow (BM)-derived RAMP1-deficient macrophages stimulated with LPS showed decreased expression of pro-inflammatory and pro-repairing genes. CGRP administration to WT mice reduced cytokine production and neutrophil accumulation. These findings indicate that RAMP1 signaling mitigates LPS-induced ALI by inactivating AMs and promoting inflammatory and repair activities of MDMs. Targeting RAMP1 signaling presents a potential therapeutic approach for the treatment of ARDS.
- 20 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 10107
Open AccessRAMP1 Signaling Mitigates Acute Lung Injury by Distinctively Regulating Alveolar and Monocyte-Derived Macrophages
Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that induces cytokine hypersecretion. Receptor activity-modifying protein (RAMP) 1, a subunit of the calcitonin gene-related peptide (CGRP) receptor, regulates the production of cytokines. This study examined the role of RAMP1 signaling during lipopolysaccharide (LPS)-induced acute lung injury (ALI). LPS administration to wild-type (WT) mice depleted alveolar macrophages (AMs) and recruited monocyte-derived macrophages (MDMs) and neutrophils. RAMP1-deficient (RAMP1−/−) mice exhibited higher lung injury scores, cytokine levels, and cytokine-producing neutrophil infiltration. RAMP1-deficient AMs produced more cytokines in response to LPS than WT AMs. Adoptive transfer of RAMP1-deficient AMs to RAMP1−/− mice increased cytokine levels and neutrophil accumulation compared to the transfer of WT AMs. RAMP1−/− mice had reduced MDM recruitment and lower pro-inflammatory and reparative macrophage profiles. Cultured bone marrow (BM)-derived RAMP1-deficient macrophages stimulated with LPS showed decreased expression of pro-inflammatory and pro-repairing genes. CGRP administration to WT mice reduced cytokine production and neutrophil accumulation. These findings indicate that RAMP1 signaling mitigates LPS-induced ALI by inactivating AMs and promoting inflammatory and repair activities of MDMs. Targeting RAMP1 signaling presents a potential therapeutic approach for the treatment of ARDS.
- Open Access
- 1 January 2024
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2024 (1) , 1727612
Airway Management for Massive Anterior Mediastinal Tumor Resection in an Infant: A Strategy Involving Spontaneous Breathing‐Preserving Endotracheal Intubation under Intravenous Anesthesia
Tracheal intubation under sedation in uncooperative infants is challenging. The case of a 4‐month‐old infant with a massive anterior mediastinal tumor and upper respiratory tract symptoms, for whom effective preoxygenation was provided with a high‐flow nasal cannula (HFNC), allowing for safe tracheal intubation in combination with a supraglottic device and local anesthetic, is reported. With careful planning of anesthesia and creative problem solving, airway management for anterior mediastinal tumors can be performed safely with the selection of an appropriate airway device. This may be a good airway management strategy for infants with mediastinal tumors or who may be expected to have ventilation difficulties.
- 1 January 2024
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2024 (1) , 1727612
Open AccessAirway Management for Massive Anterior Mediastinal Tumor Resection in an Infant: A Strategy Involving Spontaneous Breathing‐Preserving Endotracheal Intubation under Intravenous Anesthesia
Tracheal intubation under sedation in uncooperative infants is challenging. The case of a 4‐month‐old infant with a massive anterior mediastinal tumor and upper respiratory tract symptoms, for whom effective preoxygenation was provided with a high‐flow nasal cannula (HFNC), allowing for safe tracheal intubation in combination with a supraglottic device and local anesthetic, is reported. With careful planning of anesthesia and creative problem solving, airway management for anterior mediastinal tumors can be performed safely with the selection of an appropriate airway device. This may be a good airway management strategy for infants with mediastinal tumors or who may be expected to have ventilation difficulties.
- 13 May 2022
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 66 (7) , 818-822
Serum concentration of oral midazolam as pediatric preanesthetic medication and factors related to the sedation level
Background: Preanesthetic medication is important to eliminate surgical anxiety in pediatric patients and facilitate their smooth transfer to the operating room. Midazolam is the most commonly used preanesthetic medication. However, it has been reported that the sedative effect varies from patient to patient. In this study, the pharmacokinetics of midazolam were examined, and the aim was to assess the factors affecting the quality of sedation.Methods: The participants were children ranging in age from 6 months to 8 years scheduled for surgery. Midazolam 0.5 mg/kg was administered orally 30 min before entering the operating room, and the sedation level was evaluated at the time of mask application. Blood was collected after slow induction, and the serum concentration of midazolam was measured using high‐performance liquid chromatography.Results: A total of 98 patients were registered. There was no difference in serum concentrations between the effective sedation group and the ineffective sedation group (48.0 vs. 49.1 ng/mL), regardless of the effect of midazolam. Percentages of ineffective sedation by age (0 to 7 years) were 66.6%, 60%, 33.3%, 11.1%, 0%, 0%, 12.5%, and 0%, respectively. On multivariate logistic regression analysis, siblings (OR = 3.9, CI: 1.1–14.0, p = .03) and age (OR = 3.2, CI:1.2–8.5, p = .02) were related to an insufficient sedative effect.Conclusion: The serum concentration of oral midazolam reached effective levels even in patients in whom the sedative effect was inadequate. It is important to manage the perioperative period with appropriate concurrent premedication taking into account patient age and social background characteristics.Clinical trial registration: Clinical trial registry: UMIN R000052504.
- 13 May 2022
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 66 (7) , 818-822
Serum concentration of oral midazolam as pediatric preanesthetic medication and factors related to the sedation level
Background: Preanesthetic medication is important to eliminate surgical anxiety in pediatric patients and facilitate their smooth transfer to the operating room. Midazolam is the most commonly used preanesthetic medication. However, it has been reported that the sedative effect varies from patient to patient. In this study, the pharmacokinetics of midazolam were examined, and the aim was to assess the factors affecting the quality of sedation.Methods: The participants were children ranging in age from 6 months to 8 years scheduled for surgery. Midazolam 0.5 mg/kg was administered orally 30 min before entering the operating room, and the sedation level was evaluated at the time of mask application. Blood was collected after slow induction, and the serum concentration of midazolam was measured using high‐performance liquid chromatography.Results: A total of 98 patients were registered. There was no difference in serum concentrations between the effective sedation group and the ineffective sedation group (48.0 vs. 49.1 ng/mL), regardless of the effect of midazolam. Percentages of ineffective sedation by age (0 to 7 years) were 66.6%, 60%, 33.3%, 11.1%, 0%, 0%, 12.5%, and 0%, respectively. On multivariate logistic regression analysis, siblings (OR = 3.9, CI: 1.1–14.0, p = .03) and age (OR = 3.2, CI:1.2–8.5, p = .02) were related to an insufficient sedative effect.Conclusion: The serum concentration of oral midazolam reached effective levels even in patients in whom the sedative effect was inadequate. It is important to manage the perioperative period with appropriate concurrent premedication taking into account patient age and social background characteristics.Clinical trial registration: Clinical trial registry: UMIN R000052504.
- 1 April 2021
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 41 (4) , 1390-1407
Roles of Thromboxane Receptor Signaling in Enhancement of Lipopolysaccharide-Induced Lymphangiogenesis and Lymphatic Drainage Function in Diaphragm
Objective: Thromboxane is an arachidonic acid metabolite that exerts its actions through a G-protein–coupled receptor with 7 transmembrane domains. Although an arachidonic acid metabolite, prostaglandin E 2 was reported to enhance lymphangiogenesis, little is known on other arachidonic acid metabolites. In the present study, we investigated the roles of TP (thromboxane prostanoid) signaling in facilitating lymphangiogenesis during inflammation. Approach and Results: Inflammation was induced by repeated intraperitoneal injections of lipopolysaccharide, and lymphangiogenesis essential for draining peritoneal fluids was estimated in the diaphragm. Lipopolysaccharide induced lymphangiogenesis in the diaphragm in a time-dependent manner in wild-type mice. Compared with wild-type mice, lipopolysaccharide-induced lymphangiogenesis in Tp -deficient ( Tp −/− ) mouse diaphragm tissues was suppressed, and this was accompanied by reduced drainage function from the peritoneal cavity. TP-positive macrophages and T cells were accumulated in the diaphragm and produced VEGF (vascular endothelial growth factor)-C and VEGF-D in a TP-dependent manner. Removal of macrophages and T cells resulted in reduced lymphangiogenesis and lowered expressions of VEGF-C and VEGF-D. Furthermore, Tp −/− bone marrow chimeric mice exhibited reduced lymphangiogenesis. Tp knockout specific to macrophages and T cells also led to reduced lymphangiogenesis and drainage function in mice with lipopolysaccharide injections. Conclusions: The present results suggest that TP signaling exerts prolymphangiogenic activity by acting on macrophages and T cells accumulated during inflammation and that TP signaling represents a novel target for controlling lymphangiogenesis.
- 1 April 2021
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 41 (4) , 1390-1407
Roles of Thromboxane Receptor Signaling in Enhancement of Lipopolysaccharide-Induced Lymphangiogenesis and Lymphatic Drainage Function in Diaphragm
Objective: Thromboxane is an arachidonic acid metabolite that exerts its actions through a G-protein–coupled receptor with 7 transmembrane domains. Although an arachidonic acid metabolite, prostaglandin E 2 was reported to enhance lymphangiogenesis, little is known on other arachidonic acid metabolites. In the present study, we investigated the roles of TP (thromboxane prostanoid) signaling in facilitating lymphangiogenesis during inflammation. Approach and Results: Inflammation was induced by repeated intraperitoneal injections of lipopolysaccharide, and lymphangiogenesis essential for draining peritoneal fluids was estimated in the diaphragm. Lipopolysaccharide induced lymphangiogenesis in the diaphragm in a time-dependent manner in wild-type mice. Compared with wild-type mice, lipopolysaccharide-induced lymphangiogenesis in Tp -deficient ( Tp −/− ) mouse diaphragm tissues was suppressed, and this was accompanied by reduced drainage function from the peritoneal cavity. TP-positive macrophages and T cells were accumulated in the diaphragm and produced VEGF (vascular endothelial growth factor)-C and VEGF-D in a TP-dependent manner. Removal of macrophages and T cells resulted in reduced lymphangiogenesis and lowered expressions of VEGF-C and VEGF-D. Furthermore, Tp −/− bone marrow chimeric mice exhibited reduced lymphangiogenesis. Tp knockout specific to macrophages and T cells also led to reduced lymphangiogenesis and drainage function in mice with lipopolysaccharide injections. Conclusions: The present results suggest that TP signaling exerts prolymphangiogenic activity by acting on macrophages and T cells accumulated during inflammation and that TP signaling represents a novel target for controlling lymphangiogenesis.